MA43848A - Composés deutérés pour le traitement d'hémopathies malignes, compositions et procédés associés - Google Patents
Composés deutérés pour le traitement d'hémopathies malignes, compositions et procédés associésInfo
- Publication number
- MA43848A MA43848A MA043848A MA43848A MA43848A MA 43848 A MA43848 A MA 43848A MA 043848 A MA043848 A MA 043848A MA 43848 A MA43848 A MA 43848A MA 43848 A MA43848 A MA 43848A
- Authority
- MA
- Morocco
- Prior art keywords
- procedures
- treatment
- deuterated compounds
- associated compositions
- malignant hemopathies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562244267P | 2015-10-21 | 2015-10-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43848A true MA43848A (fr) | 2018-11-21 |
Family
ID=58558146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043848A MA43848A (fr) | 2015-10-21 | 2016-09-16 | Composés deutérés pour le traitement d'hémopathies malignes, compositions et procédés associés |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9688659B2 (fr) |
| EP (1) | EP3365336B1 (fr) |
| JP (1) | JP6588647B2 (fr) |
| CN (1) | CN107207469B (fr) |
| AU (1) | AU2016340740B2 (fr) |
| CA (1) | CA3002531C (fr) |
| MA (1) | MA43848A (fr) |
| WO (1) | WO2017069878A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110054614B (zh) * | 2018-01-19 | 2021-12-28 | 南京圣和药业股份有限公司 | 三嗪类idh抑制剂的可药用盐及其制备方法 |
| CN111662271B (zh) * | 2019-03-08 | 2023-11-14 | 中国药科大学 | 具有idh突变体抑制活性的化合物及其制备方法与应用 |
| US20230193336A1 (en) * | 2020-03-16 | 2023-06-22 | Double Rainbow Biosciences Inc. | Enasidenib glycosides and methods of treating diseases associated with isocitrate dehydrogenase (idh) dysfunction |
| CN111592524B (zh) * | 2020-05-20 | 2023-11-17 | 温州市天聚万迅信息科技有限公司 | 恩西德尼的制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| DK1104760T3 (da) * | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler |
| TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| EP1934201A1 (fr) * | 2005-10-06 | 2008-06-25 | Auspex Pharmaceuticals Inc. | Inhibiteurs deutériés d'atpase h+,k+ gastrique ayant des propriétés thérapeutiques renforcées |
| US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| US8778893B2 (en) * | 2009-10-05 | 2014-07-15 | Bristol-Myers Squibb Company | (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol metabolites |
| SI2800743T1 (en) * | 2012-01-06 | 2018-08-31 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and methods for their use |
| WO2015003360A2 (fr) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Composés thérapeutiquement actifs et leurs méthodes d'utilisation |
| WO2015003355A2 (fr) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Composés thérapeutiquement actifs et leurs méthodes d'utilisation |
| EA030428B1 (ru) * | 2013-08-02 | 2018-08-31 | Аджиос Фармасьютикалз, Инк. | Терапевтически активные соединения и способы их применения |
| WO2015018060A1 (fr) * | 2013-08-09 | 2015-02-12 | Agios Pharmaceuticals, Inc. | Formes cristallines de composés thérapeutiquement actifs et utilisation associée |
-
2016
- 2016-09-16 CN CN201680008147.2A patent/CN107207469B/zh active Active
- 2016-09-16 JP JP2018529008A patent/JP6588647B2/ja active Active
- 2016-09-16 AU AU2016340740A patent/AU2016340740B2/en active Active
- 2016-09-16 EP EP16857961.3A patent/EP3365336B1/fr active Active
- 2016-09-16 MA MA043848A patent/MA43848A/fr unknown
- 2016-09-16 WO PCT/US2016/052130 patent/WO2017069878A1/fr active Application Filing
- 2016-09-16 US US15/267,909 patent/US9688659B2/en not_active Expired - Fee Related
- 2016-09-16 CA CA3002531A patent/CA3002531C/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016340740B2 (en) | 2018-07-19 |
| CA3002531C (fr) | 2020-08-18 |
| CN107207469A (zh) | 2017-09-26 |
| JP6588647B2 (ja) | 2019-10-09 |
| CN107207469B (zh) | 2018-09-25 |
| EP3365336A1 (fr) | 2018-08-29 |
| CA3002531A1 (fr) | 2017-04-27 |
| JP2018531279A (ja) | 2018-10-25 |
| US9688659B2 (en) | 2017-06-27 |
| EP3365336B1 (fr) | 2023-07-26 |
| EP3365336A4 (fr) | 2018-11-21 |
| WO2017069878A1 (fr) | 2017-04-27 |
| AU2016340740A1 (en) | 2018-05-10 |
| US20170114041A1 (en) | 2017-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA42439A (fr) | Agents, utilisations et procédés pour le traitement d'une synucléinopathie | |
| MA44083A (fr) | Composés de biarylmonobactame pour le traitement d'infections bactériennes | |
| MA45192A (fr) | Traitement d'association | |
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| MA46836A (fr) | Agents, utilisations et procédés pour le traitement d'une synucléinopathie | |
| MA55629A (fr) | Compositions d'anticorps pour le traitement de tumeurs | |
| MA43135A (fr) | Compositions et méthodes pour le du traitement du cancer | |
| MA41044A (fr) | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer | |
| MA43283A (fr) | Procédés et compositions pour le traitement du cancer | |
| MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
| MA46427A (fr) | Compositions d'oligonucléotides et procédés associés | |
| MA43872A (fr) | Procédé de traitement d'une glomérulopathie à c3 | |
| MA44699A (fr) | Association d'un antagoniste du pd-1 et d'un oligonucléotide cpg du type c pour le traitement du cancer | |
| MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
| MA52134A (fr) | Compositions et procédés pour l'édition génomique | |
| MA41449A (fr) | Polythérapies pour le traitement de cancers | |
| MA43000A (fr) | Polythérapie pour le traitement de tumeurs malignes | |
| MA46791A (fr) | Composés et procédés pour réduire l'expression d'atxn3 | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| MA52098A (fr) | Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation | |
| MA46892A (fr) | Composés d'alcène tétrasubstitués et leur utilisation pour le traitement du cancer du sein | |
| MA48942A (fr) | Composés thérapeutiques, compositions et procédés d'utilisation associés | |
| MA42953A (fr) | Composés et compositions pour le traitement de troubles oculaires | |
| MA52253A (fr) | Formulation de poudre nasale pour le traitement de l'hypoglycémie |